BioVie Inc.
BIVIHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeBioVie Inc., a clinical-stage biopharmaceutical company, develops drug therapies to treat neurological and neurodegenerative disorders, and advanced liver disease in the United States. The company carries a $9.7M market cap, placing it firmly in the micro-cap category. The company develops BIV201, that is in phase 2 for the treatment of ascites due to chronic liver cirrhosis.
Market Cap
$9.7M
Beta
0.57
P/E (TTM)
—
P/E (Fwd)
-0.29
EPS (TTM)
$-3.40
EPS (Fwd)
$-4.41
ROE
-106.4%
ROA
-61.0%
Cash
$13.1M
Total Debt
$295,717
Free CF
-$13.5M
52W Change
-84.3%
Annual Financials
Cash vs Debt
Where BIVI stands vs its 150-day and 200-day moving averages
As of the July 15, 2026 close, BIVI finished 8.22% above its 150-day moving average ($1.46) and 3.95% above its 200-day moving average ($1.52). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is BIVI overbought or oversold?
At the July 15, 2026 close, BIVI's RSI(14) was 40.7, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $13.1M in cash comfortably exceeding the $296K debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Free cash flow is running at -$13.5M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -106.4% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
The relatively low beta of 0.57 suggests BIVI is a less volatile holding compared to the broader index. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence BioVie Inc.'s trajectory.